Joincare Pharmaceutical Group Industry Co., Ltd. 2024 Third Quarterly Report
Stock Code: 600380 Stock Short Name: 健康元
Joincare Pharmaceutical Group Industry Co., Ltd.
2024 Third Quarterly Report
The Board of Directors and all Directors of the Company hereby warrant that there
are no false representations, misleading statements or material omissions contained in
this announcement and accept legal responsibility for the truthfulness, accuracy and
completeness of the contents hereof.
IMPORTANT NOTICE:
The Board of Directors, the Board of Supervisors and Directors, Supervisors and senior management
of the Company hereby warrant the truthfulness, accuracy and completeness of the contents of this
quarterly report, and that there are no false representations, misleading statements or material
omissions contained herein, and severally and jointly accept legal responsibility.
The person-in-charge of the Company, the person-in-charge of accounting work and the person-in-
charge of the accounting department (the head of the accounting department) hereby warrant the
truthfulness, accuracy and completeness of the financial information contained in this quarterly report.
Whether the third quarterly financial statements have been audited.
□Yes √No
I. MAJOR FINANCIAL DATA
(I) Major Accounting Data and Financial Indicators
Unit: Yuan Currency: RMB
From the
beginning of the
For the Reporting
Item YoY change (%) year to the end of YoY change (%)
Period
the Reporting
Period
Revenues 3,664,194,805.57 -6.80 11,898,828,905.02 -5.95
Net profit attributable to
Shareholders of the listed 335,135,597.05 24.95 1,111,560,063.92 2.58
company
1 / 13
Joincare Pharmaceutical Group Industry Co., Ltd. 2024 Third Quarterly Report
Net profit attributable to
Shareholders of the listed
311,474,846.35 16.45 1,073,381,416.07 2.30
company after deduction of
extraordinary gain and loss
Net cash flow from operating
N/A N/A 2,613,605,501.06 6.25
activities
Basic earnings per share
0.18 26.01 0.59 4.63
(RMB/share)
Diluted earnings per share
0.18 26.79 0.59 4.97
(RMB/share)
Weighted average return on Increased by 0.39 Decreased by 0.40
2.32 7.82
net assets (%) percentage points percentage points
Change in the
ending amount of
As at the end of the the Reporting
As at the end of the previous year
Reporting Period Period to that of
the previous year
(%)
Total assets 36,172,500,281.87 36,358,126,258.82 -0.51
Net assets attributable to
Shareholders of the listed 14,487,774,610.56 13,755,901,924.06 5.32
company
Notes: 1. The “Reporting Period” represents the 3-month period from the beginning to the end of this
quarter, the same below.
2. From January to September 2024, the Company’s Chemical pharmaceuticals achieved revenues of
RMB5,879 million, representing a year-on-year decrease of 10.55%. Among them, revenues from
gonadotropic hormones products reached RMB2,308 million, representing a year-on-year increase of
5.46%; revenues from gastroenterology products reached RMB1,854 million, representing a year-on-year
decrease of 18.66%; revenues from respiratory formulation products reached RMB799 million,
representing a year-on-year decrease of 28.18%; revenues from psychiatry products reached RMB443
million, representing a year-on-year increase of 3.11%; and revenues from anti-infective products reached
RMB322 million, representing a year-on-year decrease of 19.46%. Revenues from APIs and intermediates
amounted to RMB3,857 million, representing a year-on-year decrease of 2.83%. Revenues from
traditional Chinese medicine (TCM) formulations were RMB1,084 million, representing a year-on-year
decrease of 16.06%. Revenues from diagnostic reagents and equipment were RMB566 million,
representing a year-on-year increase of 21.03%. Revenues from health care products amounted to
RMB262 million, representing a year-on-year increase of 97.67%, while revenues from biological
products reached RMB131 million, representing a year-on-year increase of 15.98%.
3. From January to September 2024, the Company realized net profit attributable to shareholders of
the parent of RMB1,112 million, of which Joincare (excluding Livzon Group and Livzon MAB) realized
net profit attributable to shareholders of the parent of approximately RMB479 million, representing a YoY
decrease of approximately 21.65%, and the impact of Livzon MAB on the net profit attributable to
shareholders of the parent was approximately negative RMB164 million.
2 / 13
Joincare Pharmaceutical Group Industry Co., Ltd. 2024 Third Quarterly Report
(II) Items and Amounts of Extraordinary Gains and Losses
√Applicable □N/A
Unit: Yuan Currency: RMB
From the beginning of the
For the
Item year to the end of the
Reporting Period
Reporting Period
Gains and losses on disposal of non-current assets (including the
-303,991.87 -380,432.23
reversal of previously recognized asset impairment provisions)
Government grants recognized in profit or loss for the current
period (excluding government grants that are closely related to
the business of the Company and are provided in fixed amount 44,861,228.31 97,182,195.46
or quantity continuously according to the applicable polices and
standards of the country).
Excluding effective hedging activities related to the company's
ordinary operating business, this refers to gains and losses
arising from changes in the fair value of financial assets and
15,453,330.81 -1,320,002.12
financial liabilities held by non-financial enterprises, as well as
gains and losses from the disposal of financial assets and
financial liabilities.
Other non-operating income and expenses excluding the above
-8,178,945.07 -13,068,229.51
items
Less: Effect of income tax 6,413,048.49 12,226,800.99
Effect of minority equity (after tax) 21,757,822.99 32,008,082.76
Total 23,660,750.70 38,178,647.85
For the items not listed in the “Explanatory Announcement No.1 for Public Company Information
Disclosures-Extraordinary Gains or Losses” that the company identifies as non-recurring gains and losses,
especially those with significant amounts, as well as the extraordinary gain or loss items as illustrated in
the “Explanatory Announcement No.1 for Public Company Information Disclosures-Extraordinary Gains
or Losses” which has been defined as its recurring gain or loss items, the reasons for such classification
should be explained.
□Applicable √N/A
(III) Changes in Major Accounting Data and Financial Indicators and Reasons Thereof
□Applicable √N/A
(IV) Material Changes in Other Items in Financial Statements and Financial Indicators and Reasons
Thereof
Unit: Yuan Currency: RMB
Change in
30 September 31 December
Balance Sheet proportion Main Reason
2024 2023
（%）
Mainly due to the stock
options exercised by
employees of the subsidiary
Other receivables 85,854,197.50 46,010,624.61 86.60
Livzon Group this period
have not yet received the
corresponding payment.
Mainly due to an increase in
Non-current assets due
650,845,317.12 406,376,425.44 60.16 time deposits maturing
within one year
within one year.
3 / 13
Joincare Pharmaceutical Group Industry Co., Ltd. 2024 Third Quarterly Report
Mainly due to new short-
Other current assets 294,526,056.46 77,402,185.01 280.51 term cash management
activities.
Other non-current Mainly due to new cash
1,399,815,097.39 957,224,255.77 46.24
financial assets management activities.
Mainly due to changes in the
Financial liabilities held
267,731.76 86,817.12 208.39 fair value of forward foreign
for trading
exchange contracts.
Mainly due to the
recognition of revenue from
contract advances that met
Contract liabilities 98,823,153.11 159,082,637.65 -37.88
the criteria for revenue
recognition during this
period.
Mainly due to a decrease in
Taxes payable 271,059,346.85 410,202,854.09 -33.92 corporate income tax
payable this period.
Mainly due to the transfer of
Non-current liabilities
1,930,684,639.47 718,564,144.31 168.69 long-term loans maturing
due within one year
within one year.
Mainly due to a decrease in
Other current liabilities 12,832,993.44 51,087,001.83 -74.88
estimated refund liabilities.
Mainly due to the
reclassification of long-term
Long-term loans 1,372,606,325.72 3,122,273,278.99 -56.04
loans maturing within one
year to current liabilities.
Mainly due to changes in the
fair value of other equity
instruments and fluctuations
Other comprehensive
-65,054,363.34 -12,246,131.22 N/A in exchange rates, resulting
income
in variations in foreign
currency translation
adjustments.
Change in
January to January to
Statement of Income proportion Main Reason
September 2024 September 2023
（%）
Mainly due to a decrease in
interest income from
Financial expenses -105,969,421.63 -314,423,140.18 N/A deposits and fluctuations in
foreign exchange gains and
losses.
Mainly due to fluctuations in
Gains from changes in
-5,736,443.62 -46,003,628.22 N/A the market value of held
fair value
securities investments.
Mainly due to a decrease in
long-aged accounts
Losses of credit receivable, leading to a
-797,210.83 -17,737,505.85 N/A
impairment corresponding reduction in
expected credit impairment
losses.
Mainly due to an increase in
Impairment loss of
-370,399.04 -200,478.63 N/A losses from the disposal of
assets
fixed assets.
Mainly due to changes in the
Other comprehensive fair value of other equity
-86,688,069.37 -22,658,520.87 N/A
income, net of tax instrument investments and
fluctuations in exchange
4 / 13
Joincare Pharmaceutical Group Industry Co., Ltd. 2024 Third Quarterly Report
rates, resulting in variations
in foreign currency
translation adjustments.
Change in
January to January to
Cash Flow Statement proportion Main Reason
September 2024 September 2023
（%）
Mainly due to a higher
Net cash flows from amount of investment
-1,183,961,052.92 -675,752,976.46 N/A
investing activities payments made during the
current period.
II. SHAREHOLDERS
(I) Total Number of Holders of Ordinary Shares and Number of Holders of Preferred Shares with Restored
Voting Rights and Shareholdings of Top 10 Shareholders
Unit: shares
Total number of holders of ordinary Total number of holders of preferred
shares as of the end of the Reporting 76,823 shares with restored voting rights as of the 0
Period end of the Reporting Period (if any)
Shareholdings of the top 10 shareholders
（excluding shares lent through refinancing business）
Number of Pledge, mark or lock-up
Nature of Number of Percentage shares held
Name of shareholder
shareholder shares held (%) with selling Share
restrictions status
Number
Domestic non-
Shenzhen Baiyeyuan Investment Co., Ltd.
state-owned 895,653,653 47.79 0 Pledge 55,679,725
(深圳市百业源投资有限公司)
legal person
Hong Kong Securities Clearing Company
Unknown 97,098,746 5.18 0 Unknown
Limited
Foreign legal
Might Seasons Limited 35,929,699 1.92 0 Unknown
person
Agriculture Bank of China Limited-CSI
500 Exchange Traded Index Securities Unknown 20,006,912 1.07 0 Unknown
Invest Fund
Perseverance Asset Management L.L.P–
Unknown 14,364,600 0.77 0 Unknown
Gaoyi Xiaofeng No. 2 Zhixin Fund
China Foreign Economy and Trade Trust
Co., Ltd.–Foreign Trust–Gaoyi Xiaofeng Unknown 13,130,100 0.70 0 Unknown
Hongyuan Collection Fund Trust Plan
Rui Life Insurance Co., Ltd. - Own fund Unknown 12,729,218 0.68 0 Unknown
Foreign legal
Abu Dhabi Investment Authority 12,502,378 0.67 0 Unknown
person
CPIC Fund -China Pacific Life Insurance
Co., Ltd. -with-profit insurance-CPIC
Fund China Pacific Life Equity Relative Unknown 10,170,000 0.54 0 Unknown
Income (Guaranteed Dividend) single
assets management plan
Bank of Shanghai Co., Ltd.－Yinhua CSI
Innovative Drug Industry Trading Open- Unknown 9,836,796 0.52 0 Unknown
end Index Securities Investment Fund
Shareholdings of the top 10 shareholders without selling restrictions
（excluding shares lent through refinancing business）
Number of tradable shares Class and number of shares
Name of shareholder held without selling
Class of shares Number
restrictions
5 / 13
Joincare Pharmaceutical Group Industry Co., Ltd. 2024 Third Quarterly Report
Shenzhen Baiyeyuan Investment Co., Ltd. (深圳市百业源 Ordinary shares
895,653,653 895,653,653
投资有限公司) denominated in Renminbi
Ordinary shares
Hong Kong Securities Clearing Company Limited 97,098,746 97,098,746
denominated in Renminbi
Ordinary shares
Might Seasons Limited 35,929,699 35,929,699
denominated in Renminbi
Agriculture Bank of China Limited-CSI 500 Exchange Ordinary shares
20,006,912 20,006,912
Traded Index Securities Invest Fund denominated in Renminbi
Perseverance Asset Management L.L.P–Gaoyi Xiaofeng Ordinary shares
14,364,600 14,364,600
No. 2 Zhixin Fund denominated in Renminbi
China Foreign Economy and Trade Trust Co., Ltd.–Foreign
Ordinary shares
Trust–Gaoyi Xiaofeng Hongyuan Collection Fund Trust 13,130,100 13,130,100
denominated in Renminbi
Plan
Ordinary shares
Rui Life Insurance Co., Ltd. - Own fund 12,729,218 12,729,218
denominated in Renminbi
Ordinary shares
Abu Dhabi Investment Authority 12,502,378 12,502,378
denominated in Renminbi
CPIC Fund -China Pacific Life Insurance Co., Ltd. -with-
profit insurance-CPIC Fund China Pacific Life Equity Ordinary shares
10,170,000 10,170,000
Relative Income (Guaranteed Dividend) single assets denominated in Renminbi
management plan
Bank of Shanghai Co., Ltd.－Yinhua CSI Innovative Drug
Ordinary shares
Industry Trading Open-end Index Securities Investment 9,836,796 9,836,796
denominated in Renminbi
Fund
There was no connection or acting-in-concert relationship between Shenzhen
Description of connection or acting-in-concert relationship Baiyeyuan Investment Co., Ltd., a controlling shareholder of the Company,
of the above shareholders and other shareholders; whether there is connection or acting-in-concert
relationship among other shareholders is unknown.
Description of the participation of the top 10 shareholders
and the top 10 shareholders without selling restrictions in
N/A
margin financing and securities lending and refinancing
business (if any)
Participation of shareholders holding over 5%, the top 10 shareholders, and the top 10 shareholders
without selling restriction in securities lending transactions of refinancing business
√Applicable □N/A
Unit: shares
Participation of shareholders holding over 5%, the top 10 shareholders, and the top 10 shareholders without selling restriction in securities
lending transactions of refinancing business
Number of shares lent Number of shares lent
Number of shares held in Number of shares held in
through refinancing through refinancing
ordinary and credit accounts ordinary and credit
business and not yet business and not yet
Name of shareholder at the beginning of the accounts at the end of the
returned at the beginning returned at the end of the
(Full name) Period Period
of the Period Period
Total Proportion Total Proportion Total Proportion Total Proportion
number (%) number (%) number (%) number (%)
Agriculture Bank of
China Limited-CSI 500
5,055,774 0.27 1,509,200 0.08 20,006,912 1.07 0 0.00
Exchange Traded Index
Securities Invest Fund
Bank of Shanghai Co.,
Ltd.－Yinhua CSI
Innovative Drug 8,458,496 0.45 10,000 0.001 9,836,796 0.52 0 0.00
Industry Trading Open-
end Index Securities
Investment Fund
Changes in the top 10 shareholders and the top 10 shareholders without selling restriction due to securities
lending/returning transactions of refinancing business compared to the previous period
□Applicable √N/A
6 / 13
Joincare Pharmaceutical Group Industry Co., Ltd. 2024 Third Quarterly Report
III. OTHER REMINDERS
Other important information regarding the Company’s operations during the Reporting Period to which
investors should be reminded to pay attention.
□Applicable √N/A
IV. QUARTERLY FINANCIAL STATEMENTS
(I) Audit Opinion
□Applicable √N/A
(II) Financial Statements
7 / 13
Joincare Pharmaceutical Group Industry Co., Ltd. 2024 Third Quarterly Report
Consolidated Balance Sheet
30 September 2024
Prepared by: Joincare Pharmaceutical Group Industry Co., Ltd.
Unit: Yuan Currency: RMB Audit status: Unaudited
Item 30 September 2024 31 December 2023
Current assets:
Monetary funds 14,594,801,258.03 15,691,888,314.83
Financial assets held for trading 77,343,625.25 82,899,154.24
Notes receivable 1,840,201,163.60 1,941,200,568.00
Accounts receivable 2,672,357,170.76 2,692,941,866.24
Receivables financing
Prepayments 306,162,056.96 280,102,860.94
Other receivables 85,854,197.50 46,010,624.61
In which: Interests receivable
Dividends receivable
Inventories 2,605,104,655.82 2,655,808,391.09
Contract assets
Assets held-for-sale
Non-current assets due within one year 650,845,317.12 406,376,425.44
Other current assets 294,526,056.46 77,402,185.01
Total current assets 23,127,195,501.50 23,874,630,390.40
Non-current assets:
Debt investment
Other debt investment
Long-term receivables
Long-term equity investment 1,467,317,916.58 1,411,036,353.95
Other equity instrument investments 1,066,048,054.16 1,155,283,408.36
Other non-current financial assets
Investment properties 16,327,550.42 16,958,213.00
Fixed assets 5,638,056,264.70 5,664,352,555.97
Construction in progress 662,547,623.17 531,059,118.06
Productive biological assets
Oil and gas assets
Right-of-use assets 28,190,760.95 36,233,067.49
Intangible assets 731,856,861.97 683,337,333.73
Development expenditures 461,930,852.53 483,494,487.17
Goodwill 636,339,503.82 636,339,503.82
Long-term deferred expenses 317,024,375.10 328,642,740.95
Deferred income tax assets 619,849,919.58 579,534,830.15
Other non-current assets 1,399,815,097.39 957,224,255.77
Total non-current assets 13,045,304,780.37 12,483,495,868.42
Total assets 36,172,500,281.87 36,358,126,258.82
Current liabilities:
Short-term loans 2,050,000,000.00 2,076,159,347.22
Financial liabilities held for trading 267,731.76 86,817.12
Notes payable 1,433,953,960.81 1,469,148,287.38
Accounts payable 832,051,361.15 894,286,243.28
Receipts in advance
Contract liabilities 98,823,153.11 159,082,637.65
Employee benefits payable 382,925,497.74 399,466,473.91
Taxes payable 271,059,346.85 410,202,854.09
Other payables 3,553,679,167.04 3,682,604,038.73
In which: Interests payable
8 / 13
Joincare Pharmaceutical Group Industry Co., Ltd. 2024 Third Quarterly Report
Dividends payable 10,022,086.38 12,478,280.13
Liabilities held-for-sale
Non-current liabilities due within one year 1,930,684,639.47 718,564,144.31
Other current liabilities 12,832,993.44 51,087,001.83
Total current liabilities 10,566,277,851.37 9,860,687,845.52
Non-current liabilities:
Long-term loans 1,372,606,325.72 3,122,273,278.99
Bonds payable
Lease liabilities 12,031,618.67 15,422,948.41
Long-term payables
Long-term payroll payable
Estimated liabilities
Deferred income 334,243,550.30 370,179,550.82
Deferred income tax liabilities 252,362,201.09 260,032,144.44
Other non-current liabilities 90,000,000.00 90,000,000.00
Total non-current liabilities 2,061,243,695.78 3,857,907,922.66
Total liabilities 12,627,521,547.15 13,718,595,768.18
Owner's equity (or shareholder's equity):
Paid-in capital 1,874,200,420.00 1,865,523,807.00
Other equity instruments
In which: Preferred shares
Perpetual debts
Capital reserve 1,592,054,957.78 1,601,720,087.71
Less: Treasury shares
Other comprehensive income -65,054,363.34 -12,246,131.22
Special reserve
Surplus reserve 859,046,203.77 859,046,203.77
Undistributed profits 10,227,527,392.35 9,441,857,956.80
Total owner's equity (or shareholder's equity)
14,487,774,610.56 13,755,901,924.06
attributable to the parent
Minority shareholder's equity 9,057,204,124.16 8,883,628,566.58
Total owner's equity (or shareholder's equity) 23,544,978,734.72 22,639,530,490.64
Total liabilities and owner's equity (or
36,172,500,281.87 36,358,126,258.82
shareholder's equity)
Person-in-charge of the Person-in-charge of the Person-in-charge of the
Company: Zhu Baoguo Company's accounting work: accounting department:
Qiu Qingfeng Guo Chenlu
9 / 13
Joincare Pharmaceutical Group Industry Co., Ltd. 2024 Third Quarterly Report
Consolidated Income Statement
From January to September, 2024
Prepared by: Joincare Pharmaceutical Group Industry Co., Ltd.
Unit: Yuan Currency: RMB Audit status: Unaudited
First three quarters First three quarters
Item (January to September) (January to September)
for 2024 for 2023
I. Total revenues 11,898,828,905.02 12,651,257,386.44
In which: Operating revenues 11,898,828,905.02 12,651,257,386.44
II. Total operating costs 9,121,682,123.61 9,992,088,727.85
In which: Operating costs 4,393,919,087.41 4,836,588,741.76
Operating tax and surcharges 137,567,242.03 150,278,107.37
Selling expenses 2,951,059,287.90 3,428,038,993.64
Administrative expenses 708,729,617.84 680,009,158.86
R&D expenses 1,036,376,310.06 1,211,596,866.40
Financial expenses -105,969,421.63 -314,423,140.18
In which: Interest expenses 94,972,898.62 106,424,878.84
Interest income 245,985,558.70 373,189,603.11
Add: Other income 124,184,202.58 150,725,832.49
Income from investments (loss is
51,650,239.89 58,569,845.80
indicated by“-”)
In which: Income from investments
34,370,020.06 57,873,393.21
in associates and joint ventures
Gains from derecognition of financial
assets at amortized cost
Gains from net exposure hedges (loss
is indicated by“-”)
Gains from changes in fair values
-5,736,443.62 -46,003,628.22
(loss is indicated by“-”)
Losses of credit impairment (loss is
-797,210.83 -17,737,505.85
indicated by“-”)
Assets impairment loss (loss is
-113,694,072.70 -108,440,945.45
indicated by“-”)
Gains from disposal of assets (loss is
-370,399.04 -200,478.63
indicated by“-”)
III. Operating profit (loss is indicated
2,832,383,097.69 2,696,081,778.73
by“-”)
Add: Non-operating income 6,920,279.40 6,302,873.99
Less: Non-operating expenses 19,988,508.91 23,765,998.31
IV. Total profit (loss is indicated by“-”) 2,819,314,868.18 2,678,618,654.41
Less: Income tax expenses 385,618,343.11 433,823,342.57
V. Net profit (loss is indicated by“-”) 2,433,696,525.07 2,244,795,311.84
(I) Classified by business continuity
1. Net profit from ongoing operation
2,433,696,525.07 2,244,795,311.84
(loss is indicated by“-”)
2. Net profit from discontinuing
operation (loss is indicated by“-”)
(II) Classified by ownership
1.Net profit attributable to shareholders
1,111,560,063.92 1,083,649,154.75
of the parent (loss is indicated by“-”)
2.Profit and loss of minority
1,322,136,461.15 1,161,146,157.09
shareholders (loss is indicated by“-”)
10 / 13
Joincare Pharmaceutical Group Industry Co., Ltd. 2024 Third Quarterly Report
VI. Other comprehensive income, net of
-86,688,069.37 -22,658,520.87
tax
(I) Other comprehensive income
attributable to owners of the parent, net -59,369,859.17 1,005,760.40
of tax
1. Other comprehensive income that
-58,031,748.84 -31,488,647.75
cannot be reclassified into profit or loss
(1) Changes from remeasurement of
defined benefit plans
(2) Other comprehensive income that
cannot be reclassified into profit or loss
under the equity method
(3) Changes in fair value of
-58,031,748.84 -31,488,647.75
investments in other equity instruments
(4) Changes in fair value of the
enterprise's own credit risks
2. Other comprehensive income that
-1,338,110.33 32,494,408.15
will be reclassified into profit or loss
(1) Other comprehensive income that
can be reclassified into profit or loss under -174,001.08 164,225.81
the equity method
(2) Changes in fair value of other
debt investments
(3) Amount of financial assets
reclassified into other comprehensive
income
(4) Provision for credit impairment of
other debt investments
(5) Reserve for cash flow hedges
(6) Exchange translation differences
on financial statements denominated in -1,164,109.25 32,330,182.33
foreign currencies
(7) Others
(II) Other comprehensive income
attributable to minority shareholders, net -27,318,210.20 -23,664,281.27
of tax
VII. Total comprehensive income 2,347,008,455.70 2,222,136,790.97
(I) Total comprehensive income
attributable to owners of the parent 1,052,190,204.75 1,084,654,915.15
company
(II) Total comprehensive income
1,294,818,250.95 1,137,481,875.82
attributable to minority shareholders
Ⅷ. Earnings per share
(I) Basic earnings per share (RMB/share) 0.5945 0.5682
(II) Diluted earnings per share
0.5944 0.5663
(RMB/share)
Person-in-charge of the Person-in-charge of the Person-in-charge of the
Company: Zhu Baoguo Company's accounting work: accounting department:
Qiu Qingfeng Guo Chenlu
11 / 13
Joincare Pharmaceutical Group Industry Co., Ltd. 2024 Third Quarterly Report
Consolidated Cash Flow Statement
From January to September, 2024
Prepared by: Joincare Pharmaceutical Group Industry Co., Ltd.
Unit: Yuan Currency: RMB Audit status: Unaudited
First three quarters First three quarters
Item (January to September) (January to September)
for 2024 for 2023
I. Cash flow from operating activities:
Cash received from sales of goods and rendering
12,943,223,324.92 13,510,230,759.20
of services
Tax refunds received 101,353,328.18 141,490,762.85
Other cash received related to operating activities 422,265,935.11 620,955,869.98
Subtotal of cash inflow from operating
13,466,842,588.21 14,272,677,392.03
activities
Cash paid for goods and services 3,827,753,296.70 4,573,141,561.87
Cash paid to and on behalf of employees 1,933,905,112.85 1,764,671,591.22
Payments of all types of taxes 1,480,113,236.04 1,416,153,712.56
Other cash paid related to operating activities 3,611,465,441.56 4,058,858,781.68
Subtotal of cash outflow in operating activities 10,853,237,087.15 11,812,825,647.33
Net cash flow from operating activities 2,613,605,501.06 2,459,851,744.70
II. Cash flow from investing activities:
Cash received from disposal of investment 684,870,511.47 390,344,459.46
Cash received from investment income 21,390,153.27 70,124,524.03
Net cash received from disposal of fixed assets,
474,130.00 8,042,426.01
intangible assets and other long-term assets
Net cash received from disposal of subsidiaries
8,392,000.00
and other business units
Other cash received related to investing activities 297,590,000.00
Subtotal of cash inflow from investing
715,126,794.74 766,101,409.50
activities
Cash paid for purchase and construction of fixed
737,034,937.83 753,228,828.13
assets, intangible assets and other long-term assets
Cash paid for investment 1,160,648,306.49 439,136,113.68
Net cash paid for acquisition of subsidiaries and
22,461,951.59
other business units
Other cash paid related to investing activities 1,404,603.34 227,027,492.56
Subtotal of cash outflow in investing activities 1,899,087,847.66 1,441,854,385.96
Net cash flow from investing activities -1,183,961,052.92 -675,752,976.46
III. Cash flow from financing activities:
Cash received from capital contribution 261,660,059.73 18,056,784.20
In which: Cash received from investment by
165,101,999.95 6,700,000.00
minority interests of subsidiaries
Cash received from borrowings 3,730,993,152.42 3,347,170,168.70
Other cash received related to financing activities 1,062,615.02 20,000,000.00
Subtotal of cash inflow from financing
3,993,715,827.17 3,385,226,952.90
activities
Cash repayments of amounts borrowed 4,293,197,628.28 2,592,352,425.04
Cash payments for interest expenses and
1,447,407,636.60 1,570,166,936.38
distribution of dividends or profits
In which: Dividends and profit paid minority
1,007,311,935.18 1,120,761,303.69
interests of subsidiaries
Other cash payments related to financing
400,728,019.90 1,210,358,606.39
activities
Subtotal of cash outflow in financing activities 6,141,333,284.78 5,372,877,967.81
12 / 13
Joincare Pharmaceutical Group Industry Co., Ltd. 2024 Third Quarterly Report
Net cash flow from financing activities -2,147,617,457.61 -1,987,651,014.91
IV. Effect of exchange rate fluctuations on cash
-37,426,542.59 71,991,155.94
and cash equivalents
V. Net increase in cash and cash equivalents -755,399,552.06 -131,561,090.73
Add: Opening balance of cash and cash
15,340,869,372.73 14,178,465,686.40
equivalents
VI. Closing balance of cash and cash equivalents 14,585,469,820.67 14,046,904,595.67
Person-in-charge of the Person-in-charge of the Person-in-charge of the
Company: Zhu Baoguo Company's accounting work: accounting department:
Qiu Qingfeng Guo Chenlu
(Ⅲ) Implementation of new accounting standards or interpretations of standards, for the third time from
2024 involves adjustments to the financial statements at the beginning of the year
□Applicable √N/A
Hereby the announcement is made.
Joincare Pharmaceutical Group Industry Co., Ltd.
24 October, 2024
13 / 13
